Skip to main content
Clinical Trials/NCT01977885
NCT01977885
Completed
Not Applicable

Exercise-Induced Epigenetic Modifications in Obese Aging Women

University of Georgia1 site in 1 country21 target enrollmentJune 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metabolic Syndrome
Sponsor
University of Georgia
Enrollment
21
Locations
1
Primary Endpoint
Change in CD4+T Cells from Baseline to Post-Intervention
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Our greatest public health challenge is obesity and the co-morbidities of metabolic syndrome (MetS). Age is an established risk factor for MetS and specific to women, data indicates that the prevalence of MetS increases substantially with the menopausal transition with postmenopausal women having a 60% increased risk of MetS. Menopause also contributes to reductions in strength, physical function and often psychological well-being (e.g. fatigue). Obese individuals also have: a) impaired immune function and chronic inflammatory responses associated with changes in the white blood cell population in blood and fat tissues; and, b) increased secretion of and signaling by proteins in their fat cells. Weight loss, which requires an energy deficit through increased physical activity and/or caloric restriction (EX+CR), reduces risk for MetS in older sedentary obese women by reducing insulin resistance and chronic systemic inflammation. Science and clinical practice will be advanced by examining the molecular mechanisms by which EX+CR affects risk for MetS in older women. The primary aim is to determine if CD4+ T cells will report the differential epigenetic reprogramming of relevant gene expression associated with metabolic indices resulting from EX+CR induced weight loss in older women known to be at risk for MetS. This pilot data will be used to generate an NIH proposal of the same topic. A secondary aim is to assess the impact of weight loss on physical function and psychological well-being which will provide pilot data for an additional grant proposal regarding weight management in postmenopausal women.

Registry
clinicaltrials.gov
Start Date
June 2013
End Date
December 2014
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ellen Evans

Associate Professor of Kinesiology

University of Georgia

Eligibility Criteria

Inclusion Criteria

  • Volunteer for the study
  • Age between 50 and 64 years
  • Self-identified as White or Caucasian
  • Postmenopausal
  • Sedentary (less than 1 hour each week of planned physical activity and sedentary job)
  • BMI range \>/= 25 kg/m2
  • Waist circumference \>88cm
  • Weight stable (within 2 kg) for 6 months
  • All allowable medications stable for 3 months
  • Live independently

Exclusion Criteria

  • Tobacco use
  • Normal weight (BMI \< 25 kg/m2)
  • Dietary restrictions that do not allow for the consumption of beef, as required by our dietary protocol
  • Weight loss surgery and/or weight loss medications usage
  • Mini-mental state exam score \< 25
  • Recent or history of unstable CVD
  • Cancer treatment within the last 5 years or active cancer
  • History of lung disease or COPD or severe asthma
  • History or severe arthritis or other medical condition that precludes ability to exercise to level needed by study.
  • Current diagnosis or history of balance disorders

Outcomes

Primary Outcomes

Change in CD4+T Cells from Baseline to Post-Intervention

Time Frame: Baseline (Week 0), Post-Intervention (Week 24)

The primary aim is to determine if CD4+ T cells will report the differential epigenetic reprogramming of relevant gene expression associated with metabolic indices resulting from EX+CR induced weight loss in older women known to be at risk for MetS.

Secondary Outcomes

  • Change in Physical Function over 6 Months(Baseline (Week 0), Midpoint (Week 12), Post-Intervention (Week 24))
  • Change in Psychological Well Being over 6 Months(Baseline (Week 0), Midpoint (Week 12), Post-Intervention (Week 24))

Study Sites (1)

Loading locations...

Similar Trials